Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BSP:PFRM3's EV-to-OCF is ranked better than 59.66% of 119
companies
in the Medical Distribution industry
Industry Median: 7.91
vs BSP:PFRM3: 4.49
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Profarma Distribuidora De Produtos Farmaceuticos's PE Ratio (TTM) for today is calculated as:
Profarma Distribuidora De Produtos Farmaceuticos's share price for today is R$7.50.
Profarma Distribuidora De Produtos Farmaceuticos's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1.262.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Profarma Distribuidora De Produtos Farmaceuticos EV-to-OCF Related Terms
Profarma Distribuidora De Produtos Farmaceuticos EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profarma Distribuidora De Produtos Farmaceuticos EV-to-OCF Chart
Profarma Distribuidora De Produtos Farmaceuticos Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profarma Distribuidora De Produtos Farmaceuticos EV-to-OCF vs Medical Distribution Industry
Profarma Distribuidora De Produtos Farmaceuticos's current Enterprise Value is R$2,572 Mil.
Profarma Distribuidora De Produtos Farmaceuticos's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$573 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3) has a EV-to-OCF of 4.49 as of Aug. 30, 2026. This is 11% below median its historical median of 5.06. According to the industry distribution chart, Profarma Distribuidora De Produtos Farmaceuticos ranks #48 out of 119 companies in the Medical Distribution industry, placing it in the top 40.3%.
Is Profarma Distribuidora De Produtos Farmaceuticos' EV-to-OCF too high?
Profarma Distribuidora De Produtos Farmaceuticos' current EV-to-OCF of 4.49 is 11% below median its 10-year median of 5.06. The Medical Distribution industry median EV-to-OCF is 7.91. Profarma Distribuidora De Produtos Farmaceuticos' value of 4.49 is 43.2% below this industry median. Based on the distribution chart, Profarma Distribuidora De Produtos Farmaceuticos ranks #48 out of 119 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Profarma Distribuidora De Produtos Farmaceuticos has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Profarma Distribuidora De Produtos Farmaceuticos' EV-to-OCF compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Profarma Distribuidora De Produtos Farmaceuticos ranks #48 out of 119 companies for EV-to-OCF. This puts Profarma Distribuidora De Produtos Farmaceuticos in the upper half of its industry. The industry median EV-to-OCF is 7.91. Profarma Distribuidora De Produtos Farmaceuticos' value of 4.49 is 43.2% below this benchmark. While the company's 10-year median is 5.06 vs. the industry median of 7.91, Profarma Distribuidora De Produtos Farmaceuticos has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Distribution company?
The median EV-to-OCF among Medical Distribution companies is 7.91, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Profarma Distribuidora De Produtos Farmaceuticos's current EV-to-OCF of 4.49 is 43.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median EV-to-OCF is 7.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profarma Distribuidora De Produtos Farmaceuticos's current EV-to-OCF is 4.49, which is 11% below median its own 10-year median of 5.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profarma Distribuidora De Produtos Farmaceuticos stock overvalued right now?
Based on GuruFocus' analysis, Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$8.53, compared to a current price of R$7.50 — trading 12.1% below its estimated fair value. The current EV-to-OCF is 4.49, which is 11% below median its 10-year median of 5.06 and 43.2% below the Medical Distribution industry median of 7.91. Profarma Distribuidora De Produtos Farmaceuticos' overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3), the current EV-to-OCF is 4.49 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3) Overvalued in 2026?
Based on GuruFocus' analysis, Profarma Distribuidora De Produtos Farmaceuticos stock appears to be undervalued.
The current stock price of R$7.50 is trading 12.1% below its estimated GF Value™ of R$8.53.
GuruFocus considers Profarma Distribuidora De Produtos Farmaceuticos to be Modestly Undervalued.
Key valuation signals for BSP:PFRM3:
EV-to-OCF: 4.49 (11% below median its 10-year median of 5.06)
GF Value™: R$8.53 vs. price of R$7.50 (12.1% below fair value)
Industry Position: 43.2% below the Medical Distribution median (#48 of 119)
No single metric tells the full story. See the BSP:PFRM3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profarma Distribuidora De Produtos Farmaceuticos SA is a Brazil-based company. It is engaged in wholesale and distribution of pharmaceuticals, cosmetics and similar products, and toiletries. Profarma also holds interests in other companies, regardless of their business sector. The company through its logistics department distributes products in the South, Southeast, Northeast and Center-West regions of Brazil. The firm operates in the pharmaceutical distribution, hospital and specialty, retail segments.
74GF Score
Get the complete analysis for BSP:PFRM3
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:PFRM3 has been successfully added to your 
